Despite the current high cost of Gilead Science's hepatitis C drug, the next generation version will be even more expensive. However, the company also struck deals with generic drugmakers to bring the drug to developing countries.
Despite the current high cost of Gilead Science’s hepatitis C drug, the next generation version will be even more expensive, according to Reuters.
Sovaldi costs $1,000 a pill or $84,000 for the full 12-week treatment. However, Gilead’s new all-oral treatment for the hepatitis C virus is expected to be shorter and simpler, according to Kaiser Health News. Nearly half of hepatitis C patients can be cured after 8 weeks with the new pill compared with 12 weeks on the current regimen.
According to Reuters, the new treatment could effectively cut treatment costs by one-third for patients who only stay on the treatment for the shorter timeframe. The new treatment combines Sovaldi with the experimental therapy ledipasvir. The current regimen, which includes Sovaldi, ribavirin, and interferon, costs $95,000 in total.
The new drug cures up to 99% of patients, compared with 90% on the current regimen, and US health regulators will decide by Oct. 10 whether or not to approve the drug.
Gregg Alton, Gilead’s executive vice president of corporate and medical affairs, did not give an exact price for the new medicine, but did tell Reuters that it will be less than Sovaldi plus Olysio, Johnson & Johnson’s daily protease inhibitor, which costs up to $150,000.
However, more than half the total global infected population lives in developing countries. Monday, Gilead announced agreements with 7 India-based general pharmaceutical companies: Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories, Ltd., Sequent Scientific Ltd., and Strides Arcolab Ltd.
These companies will manufacture the generic sofosbuvir and the investigational single tablet regimen of ledipasvir and sofosbuvir for 91 developing countries, which account for 54% of the world’s hepatitis C population.
According to The New York Times, Gilead will introduce the drug in India at $10 a pill, or 1% of the price in the United States. A 24-week course of treatment will cost $1,800. At the earliest, the generic version of Sovaldi will be available in India, where people are generally infected with a different form of the virus, in the second or third quarter of 2015.
“Hepatitis C is a significant public health issue worldwide, and Gilead is working to make its chronic hepatitis C medicines accessible to as many patients, in as many places, as quickly as possible,” Alton said in a statement. “In developing countries, large-volume generic manufacturing and distribution is widely regarded as a key component in expanding access to medicines. These agreements are essential to advancing the goals of our humanitarian program in these countries.”
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More